Head-To-Head Comparison: Neuphoria Therapeutics (NASDAQ:NEUP) versus Entrada Therapeutics (NASDAQ:TRDA)

Neuphoria Therapeutics (NASDAQ:NEUP) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

Insider & Institutional Ownership

15.9% of Neuphoria Therapeutics shares are held by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are held by institutional investors. 1.5% of Neuphoria Therapeutics shares are held by insiders. Comparatively, 9.5% of Entrada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Neuphoria Therapeutics has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Entrada Therapeutics has a beta of -0.19, suggesting that its stock price is 119% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Neuphoria Therapeutics and Entrada Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuphoria Therapeutics	1	2	0	0	1.67
Entrada Therapeutics	1	2	4	0	2.43

Neuphoria Therapeutics currently has a consensus target price of $7.00, indicating a potential upside of 171.32%. Entrada Therapeutics has a consensus target price of $17.75, indicating a potential upside of 243.33%. Given Entrada Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Entrada Therapeutics is more favorable than Neuphoria Therapeutics.

Valuation and Earnings

This table compares Neuphoria Therapeutics and Entrada Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuphoria Therapeutics	$1.17 million	11.93	-$13.45 million	($6.22)	-0.41
Entrada Therapeutics	$25.42 million	7.96	-$143.75 million	($3.84)	-1.35

Neuphoria Therapeutics has higher earnings, but lower revenue than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Neuphoria Therapeutics and Entrada Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Neuphoria Therapeutics	N/A	-38.31%	-28.92%
Entrada Therapeutics	-4,057.98%	-64.00%	-50.49%

Summary

Entrada Therapeutics beats Neuphoria Therapeutics on 7 of the 13 factors compared between the two stocks.

About Neuphoria Therapeutics

Neuphoria Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for neurological and psychiatric disorders. Its work is directed toward addressing significant unmet medical needs in central nervous system medicine. The company is advancing an investigational pipeline of therapeutic candidates and is primarily engaged in pharmaceutical research and development. Publicly available information does not provide sufficient detail to reliably identify specific marketed products, served geographies, or the company’s current leadership.

About Entrada Therapeutics

Entrada Therapeutics is a biotechnology company focused on developing medicines that deliver therapeutic molecules into cells. Founded in 2016 and based in Boston, Massachusetts, the company developed its Endosomal Escape Vehicle (EEV) platform to help move drug cargo across cellular membranes and reach intracellular targets. The company’s research centers on its EEV-based oligonucleotide medicines, including programs designed to address genetic causes of neuromuscular diseases. Its development work includes candidates intended to alter RNA processing for Duchenne muscular dystrophy, with programs targeting different genetic subgroups of the disease.